Our Research Results

Since we first began more than 40 years ago, Breast Cancer Trials (BCT) has contributed to more than 1,200 peer-reviewed publications and many of these research results have changed practice in the treatment and prevention of breast cancer.

The publication of the results of clinical trials research in a scientific journal or a periodic publication:

  • Fulfils the researchers’ ethical obligations to research participants and the general community;
  • Contributes to medical knowledge so doctors can make scientifically valid assessments of the benefits and risks of a new medicine or treatment for their patients.

BCT publishes study results in accordance with the BCT Publication Policy.

The citations for all of these publications are listed below, ordered by year. To search for a citation, enter a keyword/s and click search. Enclose multiple words in quotes “” to search for an exact match. Alternatively, you can search for clinical trials in a given year or for a particular clinical trial name. 

The majority of the publications can be accessed via PubMed, other research databases or publication storage systems at a university library (if you are a student/member), or directly to the journal or publication online. Many scientific journals provide articles as “open access”; however some require a subscription.

Become a Member

Are you actively involved in the conduct of breast cancer clinical trials research? Become a member today!

Become a Member

PUBLICATIONS

2026

Prognostic validation of artificial intelligence (AI)–based Stratipath breast risk stratification in TAILORx.

Hartman J, Gray RJ, Rantalainen M, Roberson S, Broeckx G, Desmedt C, Lazar AJ, Badve SS, Loi S, Sparano JA, Salgado R, TILs-WG Pathologists, and on behalf of The International Immuno-Oncology Biomarker Working Group and the TAILORx Investigators. ASCO 2026; Poster Abstract 555, Poster

Predicting chemotherapy benefit in premenopausal women with intermediate genomic scores using deep learning.

Piven A, Binenbaum Y, Aran D, Sparano JA, Kimmel R, Shamai G. ASCO 2026; Poster Abstract 602, Poster

Incremental prognostic value of an AI-derived histology signature beyond the 21-gene recurrence score: A prospective-retrospective validation in TAILORx.

Iacroix-Triki M, Gray RJ, Gaury V, Aubert V, Hocquet E, Jacobs D, Garberis I, Broeckx G, Desmedt C, Lazar AJ, Badve SS, Andre F, Loi S, Sparano JA, Salgado R, The International Immuno-Oncology Biomarker Working Group and the TAILORx Investigators. ASCO 2026; Poster Abstract 554, Poster

First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer.

Stein RC, Makris A, Macpherson IR, Hughes-Davies L, Marshall A, Pinder SE, Shaaban A, Taylor KJ, Conefrey C, Falzon MR, Naume B, Kiely BE, Cameron DA, Earl HM, Rea DW, Hall PS, Morgan A, McIntosh S, Bartlett JMS, Dunn J, OPTIMA Investigators and Trial Management Group. ASCO 2026; Oral Abstract 500, Abstract

CAPTURE: A phase II trial evaluating alpelisib + fulvestrant vs capecitabine in advanced breast cancer patients with PIK3CA-mutant circulating DNA following CDK4/6 inhibition.

Geoghegan E, Dutta AK, Niman SM, Nadkami L, Halfhide-Simpson R, Wang N, Lombard JM, Ritchie G, Cuff KE, Bae S, Whithe MA, Wilcken N, Boyle FM, Hay T, Badger HD, Francis PA, Regan MM, Zdenkowski N, Loi S, Dawson S-J. ASCO 2026; Poster Session Abstract 1064, Poster

Systemic Therapy Management Strategies for Early-Stage Breast Cancer in Australia.

Zdenkowski N, Dear R, Kumar S, Martin H, Sabanathan D, Luen SJ, Yeo B. Asia-Pacific Journal of Clinical Oncology. 2026; 1-13, https://doi.org/10.1111/ajco.70123, E-pub

Load more

Total Publications: 1369